ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)

TYO:4886 Balance Sheet

Financials in millions JPY. Fiscal year is April - March.

Assets

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Equivalents	7,108	10,126	10,603	13,738	14,505	12,103
Short-Term Investments	-	893	555	3,500	3,400	5,000
Cash & Short-Term Investments	7,108	11,019	11,158	17,238	17,905	17,103
Cash Growth	-1.71%	-1.25%	-35.27%	-3.72%	4.69%	62.67%
Receivables	16,538	15,955	15,090	15,579	15,217	14,482
Inventory	29,161	29,181	26,333	20,402	17,687	15,060
Other Current Assets	4,546	5,269	5,466	2,924	2,950	2,912
Total Current Assets	57,353	61,424	58,047	56,143	53,759	49,557
Property, Plant & Equipment	19,022	19,244	18,709	11,263	10,796	10,936
Long-Term Investments	20,119	20,756	14,472	17,765	16,400	14,244
Goodwill	2,339	2,354	4,361	-	-	-
Other Intangible Assets	6,278	6,515	2,632	2,877	4,465	6,183
Long-Term Deferred Tax Assets	1,515	2,085	2,312	2,696	1,717	2,376
Other Long-Term Assets	3,279	1	1	1	1	1
Total Assets	109,905	112,379	100,534	90,745	87,138	83,297

Liabilities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Accounts Payable	6,973	7,558	9,146	7,355	5,860	6,841
Accrued Expenses	-	1,316	1,283	1,225	1,166	1,188
Short-Term Debt	4,163	1,707	2,521	300	300	300
Current Portion of Long-Term Debt	-	1,562	1,940	4,680	3,138	1,423
Current Income Taxes Payable	-	8,020	6,367	8,690	4,947	4,867
Other Current Liabilities	8,705	2,128	1,622	1,718	2,239	1,392
Total Current Liabilities	19,841	22,291	22,879	23,968	17,650	16,011
Long-Term Debt	7,672	8,165	6,441	4,505	9,185	12,323
Pension & Post-Retirement Benefits	23	23	206	-	5,433	5,730
Other Long-Term Liabilities	5,074	5,081	1,813	343	337	341
Total Liabilities	32,610	35,560	31,339	28,816	32,605	34,405

Shareholders' Equity

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Common Stock	1,197	1,197	1,197	1,197	1,197	1,197
Additional Paid-In Capital	-	31	-	1,848	1,847	1,867
Retained Earnings	62,978	63,352	59,545	56,372	49,619	45,833
Treasury Stock	-658	-658	-704	-3,287	-3,350	-3,479
Comprehensive Income & Other	7,250	6,438	5,272	5,799	5,220	3,474
Total Common Equity	70,767	70,360	65,310	61,929	54,533	48,892
Minority Interest	6,528	6,459	3,885	-	-	-
Shareholders' Equity	77,295	76,819	69,195	61,929	54,533	48,892
Total Liabilities & Equity	109,905	112,379	100,534	90,745	87,138	83,297

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Total Debt	11,835	11,434	10,902	9,485	12,623	14,046
Net Cash (Debt)	-4,727	-415	256	7,753	5,282	3,057
Net Cash Growth	-	-	-96.70%	46.78%	72.78%	-
Net Cash Per Share	-166.47	-14.62	9.03	273.83	187.05	107.75
Filing Date Shares Outstanding	28.4	28.4	28.36	28.33	28.29	28.18
Total Common Shares Outstanding	28.4	28.4	28.36	28.33	28.29	28.18
Working Capital	37,512	39,133	35,168	32,175	36,109	33,546
Book Value Per Share	2492.14	2477.80	2302.59	2186.05	1927.97	1734.75
Tangible Book Value	62,150	61,491	58,317	59,052	50,068	42,709
Tangible Book Value Per Share	2188.68	2165.47	2056.04	2084.49	1770.12	1515.37

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 20, 2026

Data Sources Report a data error